Molecular Partners AG (XSWX:MOLN) FCF Margin % : -1,579.26% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Molecular Partners AG's Free Cash Flow for the three months ended in Dec. 2023 was CHF-16.30 Mil. Molecular Partners AG's Revenue for the three months ended in Dec. 2023 was CHF1.03 Mil. Therefore, Molecular Partners AG's FCF Margin % for the quarter that ended in Dec. 2023 was -1,579.26%.

As of today, Molecular Partners AG's current FCF Yield % is -56.25%.

The historical rank and industry rank for Molecular Partners AG's FCF Margin % or its related term are showing as below:

XSWX:MOLN' s FCF Margin % Range Over the Past 10 Years
Min: -988.85 Med: -180.39 Max: 86.22
Current: -849.86

During the past 11 years, the highest FCF Margin % of Molecular Partners AG was 86.22%. The lowest was -988.85%. And the median was -180.39%.

XSWX:MOLN's FCF Margin % is ranked worse than
74.04% of 1040 companies
in the Biotechnology industry
Industry Median: -141.08 vs XSWX:MOLN: -849.86

Molecular Partners AG FCF Margin % Historical Data

The historical data trend for Molecular Partners AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG FCF Margin % Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-14.98

-328.19

-988.85

61.80

-849.86

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-553.10	-547.67	-3,244.10	-525.30	-1,579.26

Competitive Comparison of Molecular Partners AG's FCF Margin %

For the Biotechnology subindustry, Molecular Partners AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's FCF Margin % falls into.

Molecular Partners AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Molecular Partners AG's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-59.813	/	7.038
	=	-849.86 %

Molecular Partners AG's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-16.298	/	1.032
	=	-1,579.26 %

Molecular Partners AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.